Association of Serum Ustekinumab Levels With Clinical Response in Psoriasis.

ABSTRACT:

Importance

High-cost biologic therapies have transformed the management of immune-mediated inflammatory diseases. To optimize outcomes and reduce costs, dose adjustment informed by measurement of circulating drug levels has been shown to be effective in various settings. However, limited evidence exists for this approach with the interleukin 12 and interleukin 23 inhibitor ustekinumab.

Objective

To evaluate clinical utility of therapeutic drug monitoring for ustekinumab in patients with psoriasis.

Design, setting, and participants

A prospective observational cohort of 491 adults with psoriasis was recruited to the multicenter Biomarkers of Systemic Treatment Outcomes in Psoriasis study within the British Association of Dermatologists Biologic and Immunomodulators Regi

SUBMITTER: Tsakok T 

PROVIDER: S-EPMC6751771 | biostudies-literature | 2019 Nov

REPOSITORIES: biostudies-literature